Neogenomics Inc. (NASDAQ:NEO)

CAPS Rating: 1 out of 5

Results 1 - 9 of 9

Recs

1
Member Avatar TSIF (99.96) Submitted: 7/17/2014 4:31:38 PM : Underperform Start Price: $5.17 NEO Score: +0.17

Neogenomics Inc has had a nice run since it was put on TMFSTOCKSPAM's portfolio in 2010. Sometimes a stock does advertise to gain recognition, but 98% of the time one pays to advertise...watch out....

Overall, I'm jumping on the 20% spike today on increased revenue, because the company is seriously bloated. Forward pricing growth is great, and they did cut costs, so a double plus, but at $0.01 earnings, they have a long way to grow into the current market cap. As Sean (TMFULTRALONG) wrote, the news is positive, but the reaction perhaps overdone.

http://www.fool.com/investing/general/2014/07/17/why-neogenomics-inc-stock-rocketed-higher.aspx

It's very powerful when a company goes from negative earnings to positive....if it's constant growth it could remain powerful, but I think forward pricing is too much here.

$2.1M EBITA won't go very far toward growth, and a 9X P/B is just too high.

Not one to ride too long...

Recs

0
Member Avatar OklaBoston (68.73) Submitted: 7/17/2014 4:04:24 PM : Outperform Start Price: $5.41 NEO Score: -4.44

This had been climbing for months prior to today's news.

Some short term pullback possible but ONLY short term, IMO.

Recs

0
Member Avatar NuclearSteve (69.08) Submitted: 7/17/2014 3:20:45 PM : Underperform Start Price: $5.06 NEO Score: -1.69

Shorting bio poppers strategy

Recs

0
Member Avatar jackhmr (99.25) Submitted: 5/9/2014 4:03:17 PM : Underperform Start Price: $3.17 NEO Score: -59.04

http://caps.fool.com/player/tmfstockspam.aspx

Recs

0
Member Avatar TerryHoodSr (51.12) Submitted: 12/30/2013 8:22:04 AM : Outperform Start Price: $3.75 NEO Score: +30.87

spec TP $5

Recs

0
Member Avatar franklyfoolish (< 20) Submitted: 7/23/2013 8:38:35 PM : Outperform Start Price: $3.42 NEO Score: +35.31

This is a well run company, and is run by people that have started and developed other companies to the point they went public and were successful or were bought out. Just give it a little more time.

Recs

0
Member Avatar 1OBNA (68.62) Submitted: 7/4/2013 10:14:36 PM : Outperform Start Price: $3.90 NEO Score: +11.26

A new frontier for cancer diagnoses; should provide expanded information to physicians and patients.

Recs

0
Member Avatar walhersh (96.33) Submitted: 12/11/2012 8:51:25 AM : Underperform Start Price: $3.00 NEO Score: -35.69

spam

Recs

3
Member Avatar TMFStockSpam (99.99) Submitted: 3/16/2010 4:56:32 PM : Underperform Start Price: $1.35 NEO Score: -214.92

This stock spam was originally sent to TMFBent:

New York City – March 16, 2010 -- AMI Research, a leading provider of equity research reports and a division of IR Firm, Hawk Associates Inc., announced today that it has published updated stock research coverage on NeoGenomics, Inc. (OTCBB: NGNM) based on its fourth quarter 2009 financial earnings results.

The AMI Research report provides an institutional-quality analysis of NeoGenomics’ fourth quarter providing key statistics, management, growth catalysts, financial outlook and valuation. The complete 11-page report is available for free download at the AMI Research website, http://www.amistockreports.com.

About NeoGenomics
NeoGenomics Inc., (http://www.neogenomics.org) is a CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. Staffed with specially trained hematopathologists and cytogenetic professionals, NeoGenomics Laboratories offers testing in cancer genetics, flow cytometry, immunohistochemistry and molecular diagnostics through its network of regional laboratories. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.

About AMI Research
AMI Research is a wholly owned subsidiary of Hawk Associates and provides fundamental business analysis for promising companies that do not have traditional Wall Street analyst coverage. AMI Research creates comprehensive and quality equity research reports for small cap and microcap companies that need to reach investors. These detailed reports provide retail, individual and institutional investors with an in-depth understanding of a company's intrinsic value and its technology. The AMI equity research reports detail the company's industry, strategic position, core business model, financial history and future growth catalysts.

AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst’s compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report.

******

Contact AMI Research:
Peter D’Agostino, 212.541.2465
p.dagostino@amistockreports.com
Hawk news on Facebook: http://www.facebook.com/hawkassociates
News alerts on Twitter: http://www.twitter.com/stocksonhawk.

Results 1 - 9 of 9

Featured Broker Partners


Advertisement